Delivery Order SPE2DB22D1202-SPE2DB25FVJQ4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $8,866.94 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 25, 2025, with a completion date of August 26, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, executed through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Monovisc is...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.73 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 MG/4 ML syringes (4 ML quantity) on August 12, 2025, with a completion date of August 13, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Monovisc 88 mg/4 ml syringes with a ceiling value of $2,021.59. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a competitively awarded, non-set-aside contract. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The Defense Logistics Agency awarded a $8,874.09 delivery order to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This contract employs firm fixed pricing and carries no set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a $1,471.36 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price contract, which is not set-aside, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $5,388.87 delivery order to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 mg/4 ml syringes (4 ml quantity) under a firm fixed price contract type. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency awarded a $2,194.02 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Monovisc 88 mg/4 ml syringes with a ceiling value of $2,058.76. This is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, and carries no set-aside designation. The award was made to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and distribution operations for...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJQ4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,819.92 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 27, 2025, with completion scheduled for August 28, 2025. This non-competitive, firm fixed-price delivery order represents a single procurement under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's headquarters and a key distribution point for federal medical procurement. This delivery order is executed under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive prime vendor agreement enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. Monovisc, a hyaluronic acid-based intra-articular injection used for osteoarthritis treatment, represents the type of specialized medical commodity delivered under this vehicle to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 8/27/25 |